Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study In Patients With Type 2 Diabetes Mellitus

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: November 18, 2005
Last updated: October 24, 2016
Last verified: October 2016

November 18, 2005
October 24, 2016
August 2005
October 2006   (Final data collection date for primary outcome measure)
Efficacy of GSK523338 to lower HbA1c and LDL-c
Same as current
Complete list of historical versions of study NCT00256867 on Archive Site
Safety and tolerability of GSK523338 in patients with type 2 diabetes
Same as current
Not Provided
Not Provided
A Study In Patients With Type 2 Diabetes Mellitus
A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus
This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
Drug: GSK523338
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2006
October 2006   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • A clinical diagnosis type 2 diabetes mellitus.
  • Women must not be pregnant or breastfeeding during the study and 30 days after the study.
  • Must sign an informed consent form at the study clinic.

Exclusion criteria:

  • Severe chronic diseases that would prevent from participating and completing the study by investigator's judgement.
  • Use of an investigational drug within 30 days or 5 half lives before first dose of study medication.
  • Insulin use for > 1 week in past 3 months.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada,   Mexico,   Philippines,   Puerto Rico
Not Provided
Patient-level data for this study will be made available through following the timelines and process described on this site.
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP